Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 1/2006

01-01-2006 | Editorial

Unresectable Hepatic Colorectal Metastases: Need for New Surgical Strategies

Authors: Jean-Nicolas Vauthey, MD, Eddie K. Abdalla, MD

Published in: Annals of Surgical Oncology | Issue 1/2006

Login to get access

Excerpt

In this issue of Annals of Surgical Oncology, Masi et al.1 report on a group of 74 patients who presented with unresectable hepatic colorectal metastases and were treated before surgery with a fluoropyrimidine-based chemotherapy regimen that combined oxaliplatin and irinotecan (5-fluorouracil/folinic acid, oxaliplatin, and irinotecan; FOLFOXIRI). This regimen was associated with a high response rate (72%), and surgical resection was subsequently possible in 19 responders (26%). After a median follow-up of 34 months, survival was longer in patients who had a response to chemotherapy followed by resection compared with patients who had response without surgery (37 vs. 22 months). …
Literature
1.
Masi G, Cupini S, Marcucci L, et al. Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. Ann Surg Oncol (in press)
2.
Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229–37CrossRef
3.
Giacchetti S, Itzhaki M, Gruia G, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999;10:663–9CrossRef
4.
Adam R, Avisar E, Ariche A, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal [liver] metastases. Ann Surg Oncol 2001;8:347–53CrossRef
5.
Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg 1995;19:59–71CrossRef
6.
Vauthey JN, Pawlik TM, Abdalla EK, et al. Is extended hepatectomy for hepatobiliary malignancy justified? Ann Surg 2004;239:722–32CrossRef
7.
Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004;240:644–57CrossRef
8.
Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004;15:460–6CrossRef
9.
Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 2005;200:845–53CrossRef
10.
Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004;239:818–25CrossRef
11.
Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002;235:759–66CrossRef
12.
Figueras J, Valls C, Rafecas A, Fabregat J, Ramos E, Jaurrieta E. Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases. Br J Surg 2001;88:980–5CrossRef
13.
Smith DL, Soria JC, Morat L, et al. Human telomerase reverse transcriptase (hTERT) and Ki-67 are better predictors of survival than established clinical indicators in patients undergoing curative hepatic resection for colorectal metastases. Ann Surg Oncol 2004;11:45–51CrossRef
14.
Domont J, Pawlik TM, Boige V, et al. Catalytic subunit of human telomerase reverse transcriptase is an independent predictor of survival in patients undergoing curative resection of hepatic colorectal metastases: a multicenter analysis. J Clin Oncol 2005;23:3086–93CrossRef
Metadata
Title
Unresectable Hepatic Colorectal Metastases: Need for New Surgical Strategies
Authors
Jean-Nicolas Vauthey, MD
Eddie K. Abdalla, MD
Publication date
01-01-2006
Publisher
Springer New York
Published in
Annals of Surgical Oncology / Issue 1/2006
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/ASO.2006.08.938

Other articles of this Issue 1/2006

Annals of Surgical Oncology 1/2006 Go to the issue

Original Article

Ultrasonography and Fine-Needle Aspiration Cytology Can Spare Breast Cancer Patients Unnecessary Sentinel Lymph Node Biopsy

Original Article

Prognostic Effect of Re-Excision in Adult Soft Tissue Sarcoma of the Extremity

Editorial

Decision Making for Patients With Colorectal Cancer Liver Metastases

Original Article

Primary Hyperparathyroidism in Multiple Endocrine Neoplasia Type 1: Individualized Management With Low Recurrence Rates

Original Article

Long-Term Outcomes in Patients With Calciphylaxis From Hyperparathyroidism

Original Article

Preoperative Profiling of Symptomatic Breast Cancer by Diagnostic Core Biopsy